About Hemoshear Therapeutics
Hemoshear Therapeutics is a private company based in Charlottesville, Virginia, incorporated in 2020 in Delaware. It has reported $46,602,017 raised in two offerings on Form D since February 2021.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Oct 17, 2023 | Nov 14, 2023 | $3,500,000of $8.0M target | 4 | $875K | DebtRule 506(b) | Form D ↗ |
| Feb 5, 2021 | Feb 18, 2021 | $43,102,017of $48.1M target | 17 | $2.5M | Equity, Offer and sale of Series A Preferred Stock, and the underlying shares of Common Stock issuable upon conversion thereof.Rule 506(b) | Form D ↗ |
| Total, two offerings | $46,602,017 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Hemoshear Therapeutics's Form D filed Nov 14, 2023.
MI
Michael Innes
Executive officer
DF
David Friedman
Director
PH
Patrick Horn
Executive officer
BJ
Brian Johns
Executive officer
JT
John Tilton
Director
HI
H. Watkins III
Director
JI
John Brooks III
Director
KM
Kathleen Metters
Director
AH
Aric Holsinger
Chief Financial Officer
BW
Brian Warmhoff
Executive officer and director
RG
Robert Gould
Director
Earlier filings also listed W. Thompson, Jr. (executive officer, last listed Feb 2021), James Powers (executive officer and director, last listed Feb 2021) and Brian Wamhoff (executive officer, last listed Feb 2021).